Patents by Inventor Micheal D. Gaul

Micheal D. Gaul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
    Patent number: 11919881
    Abstract: The present invention provides imidazole substituted pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: March 5, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Tho V. Thieu, Zhijie Liu, Micheal D. Gaul
  • 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
    Patent number: 11897880
    Abstract: The present invention is directed to 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: February 13, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Tianbao Lu, Zhijie Liu, Micheal D. Gaul
  • Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
    Patent number: 11845748
    Abstract: The present invention is directed to bicyclic pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: December 19, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Zhijie Liu, Micheal D. Gaul
  • Pyridine N-oxide derivatives useful as factor XIa inhibitors
    Patent number: 11814364
    Abstract: The present invention is directed to pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: November 14, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Boying Guo, Zhijie Liu, Jing Zhang, Micheal D. Gaul, Eugene B. Grant, Mark J. Macielag, Tianbao Lu, Tho V. Thieu
  • 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS
    Publication number: 20230295157
    Abstract: The present invention is directed to 3-(1H-imidazol-2-yl)-2,3,8,8a-tetrahydroindolizin-5(1H)-one derivatives, stereoisomers, isotopologues, and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: July 22, 2021
    Publication date: September 21, 2023
    Inventors: Guozhang XU, Micheal D. GAUL, Tho V. THIEU, Jing ZHANG, Mark WALL, Ling Hua GAO, Bin ZHU, Tianbao LU, Boying GUO, Zhijie LIU, Ravi NARGUND, Mark J. MACIELAG
  • Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors
    Publication number: 20230183233
    Abstract: The present invention is directed to bicyclic pyridinon-2-one and pyrimidin-4-one derivatives, stereoisomers, isotopologues, and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: July 21, 2022
    Publication date: June 15, 2023
    Inventors: Guozhang Xu, Mark J. Macielag, Micheal D. Gaul, Zhijie Liu
  • Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors
    Publication number: 20230097157
    Abstract: The present invention is directed to bicyclic pyridinon-2-one and pyrimidin-4-one derivatives, stereoisomers, isotopologues, and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: July 21, 2022
    Publication date: March 30, 2023
    Inventors: Guozhang Xu, Mark J. Macielag, Micheal D. Gaul, Tho V. Thieu, Zhijie Liu
  • PYRIDINE N-OXIDE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS
    Publication number: 20230091768
    Abstract: The present invention is directed to pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: March 17, 2022
    Publication date: March 23, 2023
    Inventors: Guozhang Xu, Boying Guo, Zhijie Liu, Jing Zhang, Micheal D. Gaul, Eugene B. Grant, Mark J. Macielag, Tianbao Lu, Tho V. Thieu
  • 7,8-DIHYDROBENZO[E]PYRIDO[3,4-C]AZOCINE-2,5(3H,6H)-DIONE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS
    Publication number: 20220389005
    Abstract: The present invention is directed to 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: April 29, 2022
    Publication date: December 8, 2022
    Inventors: Guozhang Xu, Tianbao Lu, Zhijie Liu, Micheal D. Gaul
  • SUBSTITUTED PYRIDINE N-OXIDE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS
    Publication number: 20220315561
    Abstract: The present invention provides imidazole substituted pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: March 17, 2022
    Publication date: October 6, 2022
    Inventors: Guozhang Xu, Tho V. Thieu, Zhijie Liu, Micheal D. Gaul
  • BICYCLIC PYRIDINE N-OXIDE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS
    Publication number: 20220306632
    Abstract: The present invention is directed to bicyclic pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: March 17, 2022
    Publication date: September 29, 2022
    Inventors: Guozhang Xu, Zhijie Liu, Micheal D. Gaul
  • QUINAZOLIN-4-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS
    Publication number: 20220267298
    Abstract: The present invention is directed to quinazolin-4-one derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GRK2, including the treatment of for example, cardiac failure, cardiac hypertrophy, hypertension, Type II diabetes Mellitus, NASH, NAFLD, End-stage kidney disease, kidney failure, etc.
    Type: Application
    Filed: July 29, 2020
    Publication date: August 25, 2022
    Inventors: Guozhang Xu, Micheal D. Gaul
  • PHTHALAZIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS
    Publication number: 20220242850
    Abstract: The present invention is directed to phthalazin-1-one derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GRK2, including the treatment of for example, cardiac failure, cardiac hypertrophy, hypertension, Type II diabetes Mellitus, NASH, NAFLD, End-stage kidney disease, kidney failure, etc.
    Type: Application
    Filed: June 29, 2020
    Publication date: August 4, 2022
    Inventors: Guozhang Xu, Micheal D. Gaul
  • ISOINDOLIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS
    Publication number: 20220009906
    Abstract: The present invention is directed to isoindolin-1-one derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GRK2, including, but not limited to, cardiac failure, cardiac hypertrophy, hypertension, Type II diabetes Mellitus, NASH, NAFLD, end stage chronic kidney disease, kidney failure, etc.
    Type: Application
    Filed: June 24, 2021
    Publication date: January 13, 2022
    Inventors: Guozhang Xu, Eugene B. Grant, Gee-Hong Kuo, Micheal D. Gaul
  • Substituted piperidinyl-carboxamide derivatives useful as SCD 1 inhibitors
    Patent number: 9238658
    Abstract: The present invention is directed to novel piperidinyl-carboxamide derivatives, pharmaceutical compositions containing them and their use as inhibitors of SCD1, useful in the treatment of obesity, type-II diabetes and other related metabolic disorders.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: January 19, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Shyh-Ming Yang, Gee-Hong Kuo, Micheal D. Gaul, Thomas A. Rano
  • Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors
    Patent number: 9102669
    Abstract: The present invention is directed to novel piperidinyl-pyridazinyl derivatives, pharmaceutical compositions containing them and their use as inhibitors of SCD1, useful in the treatment of obesity, type-II diabetes and other related metabolic disorders.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: August 11, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Shyh-Ming Yang, Gee-Hong Kuo, Micheal D. Gaul, Thomas A. Rano
  • SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS
    Publication number: 20140371220
    Abstract: The present invention is directed to novel piperidinyl-pyridazinyl derivatives, pharmaceutical compositions containing them and their use as inhibitors of SCD1, useful in the treatment of obesity, type-II diabetes and other related metabolic disorders.
    Type: Application
    Filed: December 5, 2012
    Publication date: December 18, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Shyh-Ming Yang, Gee-Hong Kuo, Micheal D. Gaul, Thomas A. Rano
  • SUBSTITUTED PIPERIDINYL-CARBOXAMIDE DERIVATIVES USEFUL AS SCD 1 INHIBITORS
    Publication number: 20140364393
    Abstract: The present invention is directed to novel piperidinyl-carboxamide derivatives, pharmaceutical compositions containing them and their use as inhibitors of SCD1, useful in the treatment of obesity, type-II diabetes and other related metabolic disorders.
    Type: Application
    Filed: December 5, 2012
    Publication date: December 11, 2014
    Inventors: Shyh-Ming Yang, Gee-Hong Kuo, Micheal D. Gaul, Thomas A. Rano
  • Hetero isonipecotic modulators of vanilloid VR1 receptor
    Patent number: 8604190
    Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to hetero isonipecotic amides that are potent modulators of VR1 which are useful for the treatment and prevention of disease conditions in mammals.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: December 10, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Micheal D. Gaul, Bao-Ping Zhao, Daniel A. Hutta
  • HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR
    Publication number: 20100256359
    Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to hetero isonipecotic amides that are potent modulators of VR1 which are useful for the treatment and prevention of disease conditions in mammals.
    Type: Application
    Filed: October 6, 2009
    Publication date: October 7, 2010
    Inventors: Micheal D. Gaul, Bao-Ping Zhao, Daniel A. Hutta